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Abstract
A fourteen years-old boy was treated post-operatively with proton therapy for a recurrent low-grade oligodendro-
glioma located in the tectal region. Six months after the end of irradiation (RT), a new enhancing lesion appeared
within the radiation fields. To differentiate disease progression from radiation-induced changes, dynamic suscept-
ibility contrast-enhanced (DSCE) MRI was used with a T2* sequence to study perfusion and permeability character-
istics simultaneously. Typically, the lesion showed hypoperfusion and hyperpermeability compared to the
controlateral normal brain. Without additional treatment but a short course of steroids, the image disappeared over
a six months period allowing us to conclude for a pseudo-progression. The patient is alive in complete remission
more than 2 years post-RT.
Background
The occurrence of new contrast enhancing lesions on
routine MRI follow-up after radiation therapy (RT) for
brain gliomas was observed more than ten years ago but
remains problematic because standard MR imaging
techniques do not allow a clear distinction between
recurrent tumour and radiation-induced lesions [1,2].
Recently, “pseudo-progression” was defined as conven-
tional MR images compatible with progression, occur-
ring shortly after concomitant radio-chemotherapy
(CRC), as a transient phenomenon with spontaneous
improvement or stabilization after several months [3-5].
This was mainly described in adult and paediatric popu-
lations with high-grade gliomas whose new standard of
care is CRC followed by adjuvant chemotherapy [6,7].
We report here a clinical case showing a new con-
trast-enhancing lesion discovered on a systematic MRI
proposed to a fourteen years-old boy treated six months
before for a recurrent low-grade glioma by surgery and
proton-therapy. Dynamic Susceptibility Contrast (DSC)
MR imaging and planned follow-up lead to the diagnosis
of pseudo-progression. This phenomenon has rarely
been described in children with supra-tentorial low-
grade gliomas after proton beam RT, particularly with
this type of advanced MR technique.
Case Presentation
Initial presentation and conventional MRI description
A healthy ten year-old boy with tinnitus and bilateral
papillary oedema underwent a brain MRI showing a
small tumour of the tectal plate. The lesion presented a
signal of low intensity on T1-weighted and a high signal
on T2-weighted sequences. No contrast enhancement
was visible. The process was responsible for triventricu-
lar hydrocephalus by aqueduct compression. The first
treatment was a ventriculocysternostomy followed, fif-
teen months later, by a partial resection when the lesion
increased in size. Histopathological diagnosis was a
grade II oligodendroglioma (WHO classification), with a
proliferation index (MIB 1) of 5%. Three years after the
first surgery, a systematic follow-up MRI revealed a
recurrence localized on the quadrigeminal plate, close to
the left thalami and the third ventricle, again without
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attempted, showing the same histology, but a tumour
residue was left on the left thalamus (Figure 1). Treat-
ment was completed six weeks later by RT using proton
beams, delivering 54 Gy in 30 fractions of 1.8 Gy. Radia-
tion fields encompassed the medial parts of the thalami
(Figure 1C, D). Radiological and clinical data were then
evaluated every 3 months thereafter. Six months after
RT, systematic MRI found obvious development of a
new lesion with an important contrast enhancement and
mass effect on the third ventricle (Figure 2), however
the patient remained asymptomatic.
Conventional and Dynamic MRI with Permeability
visualization and Perfusion estimate
In order to more accurately differentiate tumour recur-
rence from radiation-induced changes, a DSC-MRI was
performed as described previously [8,9]. The T2*
sequence was used in order to assess simultaneously
perfusion and permeability characteristics, as recently
proposed for predicting risk of recurrence in adult low-
grade gliomas [10]. In this case, the typical combination
of a focused area of high permeability strictly superim-
posed on the contrast enhancing lesion combined with
the absence of high perfusion estimate in the same
region (Figure 3) was compatible with post-radiation
modifications, as recently suggested by Hu et al. They
found a direct correlation between image-guided tissue
histopathology and localized DSC perfusion MR imaging
measurements in a series of adult high-grade gliomas
[11]. Consequently, we favoured the hypothesis of a
delayed radiation injury and began a treatment with oral
steroids (prednisone) at one mg/kg/d for one month
before clinical and radiological reappraisal. After one
month, decrease in size of contrast enhancement
became significant while the patient remained asympto-
matic. Steroids were therefore discontinued. Gradual
improvement continued on conventional MRI and dis-
appearance of both contrast enhancement and high per-
meability area strongly suggested a pseudo-progression
rather than recurrent disease. Follow-up MRI at nine
months post-RT showed a complete resolution of the
gadolinium uptake and no detectable microvascular
leakage (Figure 4). At last follow-up, patient is still in
complete remission, more than two years post-RT.
Post-treatment modifications, evolution with time and
micro-vascular hypothesis
Subacute radiation-induced modifications have been
described previously in childhood gliomas, with or
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Figure 1 Conventional MR imaging, Target volume and Dosimetry of a Low-grade Glioma. A left thalamic low-grade oligodendroglioma
in a 10 year-old boy after partial resection, without contrast enhancement. [A] T1-weighted transaxial MR image after administration of
intravenous Gd-DTPA [B] T2 -weighted sequence which shows ill-defined nodular images. [C] Representation of Gross tumor volume (in red) and
Clinical target volume (in green). [D] Radiation field encompassing medial part of the left thalamus.
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[1,12-14]. In adults, these changes are more and more
reported after combined radio-chemotherapy [4,5,15].
MRI findings usually consist on new contrast enhancing
mass on T1-weighted imaging with gadolinium, which is
indistinguishable from tumour progression. It occurs
usually within the irradiated tumour volume but radia-
tion-induced lesions could be located less commonly in
the controlateral hemisphere, remotely from the primary
tumour site [6]. To our knowledge, it is the first case of
pseudo-progression fully described after exclusive pro-
ton RT. Here, time of occurrence was delayed (6
months) since the typical time frame is rather within 3
months after chemo-radiation, possibly due to the
absence of concomitant chemotherapy [3,5,6]. Cerebral
injury has been classified according to time to appear-
ance after RT [8] as “acute”, with brain oedema occur-
ring during RT, mostly transient and reversible;
subacute or “early delayed” injury, occurring a few
weeks to three months post-RT, improving within six
weeks; late injury, occurring months to years post-RT,
including true radionecrosis. It is often irreversible, pro-
gressive, and possibly lethal and constitutes the major
dose-limiting clinical complication of brain irradiation,
particularly in children. Pseudo-progression (PsP) could
be considered as a pathological continuum between
acute post-RT reaction and treatment-related necrosis
[6]. Mechanisms behind these events are not fully
understood but are probably related to micro-vessels
changes. Post-RT brain injury induces a focal tissue
reaction with inflammatory component and increased
capillary permeability, causing fluid transudation into
the interstitial space and brain oedema. Transient
alterations in the blood-brain barrier may be responsible
for new or increased contrast enhancement, falsely sug-
gesting tumour progression, with low perfusion values
[11].
Role of PET and advanced MR techniques in the diagnosis
of “pseudo-progresion”, clinical implication
This DSC-MR technique evaluates tissue changes, close
to the physiopathology of PsP, whereas metabolic tools
as FDG-PET or MR spectroscopy (MRS) analyse level of
Figure 2 Conventional MR imaging before and six months after
exclusive Proton therapy. [A] T1-weighted transaxial MR image
after administration of intravenous (iv) Gd-DTPA, one week before
radiation. [B] The same sequence, six months after the end of
irradiation (54 Gy), showing a strong contrast enhancement with a
subtle mass effect (yellow arrow).
Figure 3 Six months after irradiation: superimposed MR
images with T1-weighted sequence after iv Gadolinium
injection and co-registered Perfusion (left) and Permability
maps (right). [A] Gradient-echo axial image with color overlay map
showing no focus of hyperperfusion in regard of the strong contrast
enhancement [B] The superimposed Permeability map with a strong
microvascular leakage (yellow arrow) strictly corresponding with the
enhanced area in the T1-weighted sequence.
Figure 4 Nine months after irradiation: complete disappearance
of the contrast enhancement (left) and no detectable
Permeability (right). [A] T1-weighted transaxial MR image after
administration of iv Gd-DTPA and [B] the superimposed Permeability
map, with no contrast enhancement or detectable microvascular
leakage. To be noted, a subtle hypersignal, pre-existing to the
irradiation, as a post-operative modification (yellow arrow).
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MRS can distinguish recurrent true necrosis from active
tumour [16-18] but it needs long acquisition time. In
18FDG-PET, FDG uptake is not specific of tumour tissue
and false positive can be observed in non malignant
inflammatory processes. The use of aminoacid tracers as
11C-methionine better discriminates post-RT necrosis
from tumour recurrence [19] but it is rarely available in
daily practice. Recently, the DSC-MR technique was
proposed for adult high-grade gliomas in this situation
[20,21] as an alternative tool. It can be incorporated in
the routine follow-up, within the interval of three to six
months post-RT where PsP can be observed. Impor-
tantly, there is a risk of including children with gliomas
in phase II studies for “recurrent disease” that would be
spontaneously reversible, leading to false positive results,
consequently delivering salvage treatments for “pseudo-
progressive” patients who could be, at the contrary,
potentially long term survivors [15].
Conclusion
The lack of typical clinical symptoms and the limits of
anatomical MRI techniques imply that any subacute
change suggesting disease progression may be consid-
ered as possible PsP. Post-RT therapy should not be
interrupted too early [22] and DSC-MRI could help for
distinguishing PsP from real progression.
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